Zuzanna Kanduła1, Michał Janowski2, Barbara Więckowska3, Edyta Paczkowska2, Krzysztof Lewandowski4. 1. Department of Hematology and Bone Marrow Transplantation, Poznań University of Medical Sciences, Poznań, Poland. zuzannakandula@gmail.com. 2. Department of General Pathology, Pomeranian Medical University, Szczecin, Poland. 3. Department of Computer Science and Statistics, Poznań University of Medical Sciences, Poznań, Poland. 4. Department of Hematology and Bone Marrow Transplantation, Poznań University of Medical Sciences, Poznań, Poland.
Abstract
INTRODUCTION: Despite comparatively favourable prognosis in polycythemia vera (PV) patients (pts), the overall survival is shorter compared to the age-matched general population. The aim of the study was to evaluate the impact of chosen laboratory and genetic factors on the individual disease outcome, i.e. risk of thrombosis, myelofibrosis/blastic transformation and death. MATERIALS AND METHODS: The study group consisted of 151 pts and 57 healthy donors (HD). RESULTS: JAK2V617F mutation was found in 96.7% (146/151) of the studied pts. JAK2 exon 12 mutations were identified in 2 individuals. The coexistence of JAK2V617F and JAK2 exon 12 mutation was confirmed in 2 other pts. In one case, neither JAK2V617F nor JAK2 exon 12 mutation was found. The presence of ten different non-driver mutations (ASXL1, SRSF2, U2AF1, IDH2) in eight of the analyzed pts (5.3%) was confirmed. The overall frequency of thrombotic events (TE) in the studied PV group was 23.8% (36/151). In patients with TE, median platelet count was lower than in pts without TE. Thrombotic risk did not depend on JAK2 rs12343867, TERT rs2736100, OBFC1 rs9420907 SNV, however, we found a novel strong tendency towards statistical significance between the CC genotype miR-146a rs2431697 and thrombosis. The disease progression to fibrotic phase was confirmed in 9% of the pts. Fibrotic transformation in PV pts was affected mainly by JAK2V617F variant allele frequency (VAF) and the presence of coexisting non-driver variants. The high JAK2V617F VAF and elevated white blood cell (WBC) count at the time of diagnosis were associated with an increased risk of death. CONCLUSION: Therefore, in our opinion, complex, laboratory and genetic PV pts evaluation at the time of diagnosis should be incorporated into a new prognostic scoring system to more precisely define the PV prognosis and to optimize the therapeutic decision-making process.
INTRODUCTION: Despite comparatively favourable prognosis in polycythemia vera (PV) patients (pts), the overall survival is shorter compared to the age-matched general population. The aim of the study was to evaluate the impact of chosen laboratory and genetic factors on the individual disease outcome, i.e. risk of thrombosis, myelofibrosis/blastic transformation and death. MATERIALS AND METHODS: The study group consisted of 151 pts and 57 healthy donors (HD). RESULTS: JAK2V617F mutation was found in 96.7% (146/151) of the studied pts. JAK2 exon 12 mutations were identified in 2 individuals. The coexistence of JAK2V617F and JAK2 exon 12 mutation was confirmed in 2 other pts. In one case, neither JAK2V617F nor JAK2 exon 12 mutation was found. The presence of ten different non-driver mutations (ASXL1, SRSF2, U2AF1, IDH2) in eight of the analyzed pts (5.3%) was confirmed. The overall frequency of thrombotic events (TE) in the studied PV group was 23.8% (36/151). In patients with TE, median platelet count was lower than in pts without TE. Thrombotic risk did not depend on JAK2 rs12343867, TERT rs2736100, OBFC1 rs9420907 SNV, however, we found a novel strong tendency towards statistical significance between the CC genotype miR-146a rs2431697 and thrombosis. The disease progression to fibrotic phase was confirmed in 9% of the pts. Fibrotic transformation in PV pts was affected mainly by JAK2V617F variant allele frequency (VAF) and the presence of coexisting non-driver variants. The high JAK2V617F VAF and elevated white blood cell (WBC) count at the time of diagnosis were associated with an increased risk of death. CONCLUSION: Therefore, in our opinion, complex, laboratory and genetic PV pts evaluation at the time of diagnosis should be incorporated into a new prognostic scoring system to more precisely define the PV prognosis and to optimize the therapeutic decision-making process.
Authors: Alberto Alvarez-Larrán; Beatriz Bellosillo; Arturo Pereira; Ana Kerguelen; Juan Carlos Hernández-Boluda; Luz Martínez-Avilés; Concepción Fernández-Rodríguez; Montse Gómez; Luis Lombardía; Anna Angona; Agueda Ancochea; Alicia Senín; Raquel Longarón; Blanca Navarro; María Collado; Carlos Besses Journal: Am J Hematol Date: 2014-02-21 Impact factor: 10.047
Authors: A Birdane; I C Haznedaroğlu; N Bavbek; A Koşar; Y Büyükaşik; O Ozcebe; S V Dündar; S Kirazli Journal: Clin Appl Thromb Hemost Date: 2005-04 Impact factor: 2.389
Authors: Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman Journal: Blood Date: 2016-04-11 Impact factor: 22.113
Authors: G Barosi; R A Mesa; J Thiele; F Cervantes; P J Campbell; S Verstovsek; B Dupriez; R L Levine; F Passamonti; J Gotlib; J T Reilly; A M Vannucchi; C A Hanson; L A Solberg; A Orazi; A Tefferi Journal: Leukemia Date: 2007-08-30 Impact factor: 11.528
Authors: Ana B Arroyo; María P Fernández-Pérez; Alberto Del Monte; Sonia Águila; Raúl Méndez; Rebecca Hernández-Antolín; Nuria García-Barber; Ascensión M de Los Reyes-García; Paula González-Jiménez; María I Arcas; Vicente Vicente; Rosario Menéndez; Vicente Andrés; Rocío González-Conejero; Constantino Martínez Journal: Haematologica Date: 2021-06-01 Impact factor: 9.941